Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Common Equity (2019 - 2025)

Historic Common Equity for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $966.0 million.

  • Beam Therapeutics' Common Equity rose 2207.52% to $966.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $966.0 million, marking a year-over-year increase of 2207.52%. This contributed to the annual value of $733.5 million for FY2024, which is 2524.98% down from last year.
  • Beam Therapeutics' Common Equity amounted to $966.0 million in Q3 2025, which was up 2207.52% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Common Equity registered a high of $1.1 billion during Q1 2025, and its lowest value of $422.4 million during Q1 2021.
  • In the last 5 years, Beam Therapeutics' Common Equity had a median value of $811.6 million in 2023 and averaged $815.3 million.
  • In the last 5 years, Beam Therapeutics' Common Equity skyrocketed by 32675.55% in 2021 and then plummeted by 2524.98% in 2024.
  • Over the past 5 years, Beam Therapeutics' Common Equity (Quarter) stood at $826.7 million in 2021, then fell by 11.28% to $733.5 million in 2022, then soared by 33.79% to $981.3 million in 2023, then fell by 25.25% to $733.5 million in 2024, then soared by 31.69% to $966.0 million in 2025.
  • Its Common Equity stands at $966.0 million for Q3 2025, versus $1.0 billion for Q2 2025 and $1.1 billion for Q1 2025.